This result, however, is in contrast with four prior published studies that analyze KIR/KIR-L genotypes in NB patients receiving anti-GD2 mAb therapy and reported a better outcome in KIR/KIR-L mismatch patients [31,41,42]. This evidence concerns the gene KIR3DL1 and neuroblastoma.